Physician profile
Shannon M Marsh
NPI 1114339389
$2,752.66
in general payments reported to CMS, 2019-2025
23 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Family Health provider received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $423 · 2023: $1,363 · 2024: $335 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296 · Travel and Lodging: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.50 |
| Travel and Lodging | $828.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $828.93 | 2023-2024 | Cardiomems |
| Novo Nordisk INC | $517.65 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $181.39 | 2023-2024 | |
| Lilly USA, LLC | $177.87 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $165.98 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $109.34 | 2023-2024 | Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $91.16 | 2021-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $82.91 | 2023-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.35 | 2021-2022 | |
| Pfizer INC. | $72.35 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $72.18 | 2022 | |
| Abbvie INC. | $64.68 | 2023-2024 | |
| Astellas Pharma US INC | $64.44 | 2025 | Veozah |
| Dexcom, INC. | $49.65 | 2024-2025 | Dexcom G6 Transmitter |
| Kiniksa Pharmaceuticals International, Plc | $34.14 | 2024 | Arcalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $27.50 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $25.00 | 2023 | Aplenzin |
| Sanofi Pasteur INC. | $24.40 | 2023 | |
| Amarin Pharma, INC. | $21.34 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.82 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $14.83 | 2024 | Farxiga |
| Exact Sciences Corporation | $14.75 | 2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.